532605 Sigma-AldrichAurora A/MYCN Dual Inhibitor, CD532 - CAS 1639009-81-6 - Calbiochem
A cell permeable, highly potent, selective inhibitor of Aurora A (IC₅₀ = 48 nM). Disrupts MYCN-Aurora A complex.
More>> A cell permeable, highly potent, selective inhibitor of Aurora A (IC₅₀ = 48 nM). Disrupts MYCN-Aurora A complex. Less<<同義語: Aurora A Inhibitor, CD532, MYCN Inhibitor, CD532
お勧めの製品
概要
| Replacement Information |
|---|
主要スペック表
| CAS # | Empirical Formula |
|---|---|
| 1639009-81-6 | C₂₆H₂₅F₃N₈O |
価格&在庫状況
| カタログ番号 | 在庫状況 | 包装 | Qty/Pk | 価格 | 数量 | |
|---|---|---|---|---|---|---|
| 5.32605.0001 |
|
ガラスビン | 10 mg |
|
— |
| References | |
|---|---|
| References | Lee, J.K., et al. 2016. Cancer Cell. 29, In press. Gustafson, W. C., et al. 2014. Cancer Cell. 26, 414. |
| Product Information | |
|---|---|
| CAS number | 1639009-81-6 |
| Form | Tan solid |
| Hill Formula | C₂₆H₂₅F₃N₈O |
| Chemical formula | C₂₆H₂₅F₃N₈O |
| Reversible | Y |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | Aurora A |
| Primary Target IC<sub>50</sub> | 48 nM |
| Secondary target | MYCN |
| Purity | ≥97% by HPLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | Y |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| カタログ番号 | GTIN |
| 5.32605.0001 | 04055977281804 |
Documentation
Aurora A/MYCN Dual Inhibitor, CD532 - CAS 1639009-81-6 - Calbiochem (M)SDS
| タイトル |
|---|
参考資料
| 参考資料の概要 |
|---|
| Lee, J.K., et al. 2016. Cancer Cell. 29, In press. Gustafson, W. C., et al. 2014. Cancer Cell. 26, 414. |
技術情報
| タイトル |
|---|
| Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
| White Paper: Further considerations of antibody validation and usage. |



